

June 15, 2017

The Manager- Listing  
**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing  
**National Stock Exchange of India Limited**  
Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai - 400051

Dear Sir(s),


**Sub: AstraZeneca Pharma India Limited receives Import and Market permission in Form 45 (Marketing Authorization) from Drug Controller General of India (DCGI) for FDC of Budesonide 320 µg +Formoterol Fumarate Dihydrate 9 µg inhalation powder (Symbicort® Turbuhaler® 320/9 µg).**

This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for FDC of Budesonide 320 µg +Formoterol Fumarate Dihydrate 9 µg inhalation powder.

FDC of Budesonide 320 µg + Formoterol Fumarate Dihydrate 9 µg inhalation powder (**Symbicort® Turbuhaler® 320/9 µg**) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting β-agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations.

Kindly take the same on record.

For AstraZeneca Pharma India Limited



**Pratap Rudra**  
Company Secretary & Legal Counsel